Effects of Thai Dance Meditation Exercise on Renal and Cerebrovascular Function in Elderly With Diabetic Kidney Disease
NCT06578325, Not applicable, Completed, Chulalongkorn University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Thai Dance Meditation Exercise on Renal and Cerebrovascular Function in Elderly With Diabetic Kidney Disease | ClinicalTrials.gov |
| NCT number | NCT06578325 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Chulalongkorn University | ClinicalTrials.gov |
| Conditions | Diabetic Kidney Disease | ClinicalTrials.gov |
| Interventions | Thai dance meditation, No intervention | ClinicalTrials.gov |
| First posted | 2024-08-29 | ClinicalTrials.gov |
| Last updated | 2024-08-29 | ClinicalTrials.gov |
Registered outcomes 38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Blood pressure | Change from baseline systolic blood pressure, diastolic blood pressure, and mean arterial pressure at 12 weeks.] | Blood pressure (systolic blood pressure, diastolic blood pressure, and mean arterial pressure) in mmHg will be measured with automated blood pressure in mmHg device (CARESCAPE V100, GE Dinamap). | ClinicalTrials.gov |
| Primary | Heart rate | Change from baseline heart rate at 12 weeks | Heart rate in beats per minute will be measured with automated blood pressure in beat per minute device (CARESCAPE V100, GE Dina map). | ClinicalTrials.gov |
| Primary | Body fat | Change from baseline body fat at 12 weeks | Body fat in percent will be measured with dual energy x-ray absorptiometry in percent (Prodigy-Pro, GE healthcare). | ClinicalTrials.gov |
| Primary | Muscle mass and Weight | Change from baseline muscle mass and weight at 12 weeks. | Muscle mass and weight in kilograms will be measured with dual energy x-ray absorptiometry in kilogram (Prodigy-Pro, GE healthcare). | ClinicalTrials.gov |
| Primary | Arterial stiffness | Change from baseline brachial-ankle pulse wave velocity at 12 weeks | Arterial stiffness will be measured with brachial-ankle pulse wave velocity in centimeter per second (VP-1000 plus, omrom Healthcare). | ClinicalTrials.gov |
| Primary | Macro vascular function | Change from baseline brachial artery flow-mediated dilatation at 12 weeks | Macro vascular function will be measured by brachial artery flow-mediated dilatation in percent with ultrasonography equipment EPIQ 5G, Phillips. | ClinicalTrials.gov |
| Primary | Renal function | Change from baseline Blood urea nitrogen at 12 weeks. | Blood urea nitrogen (BUN) in milligram per deciliter will be measure by Kinetic test with urease and glutamate dehydrogenase with urease/glutamate dehydrogenase coupled enzymatic (Coupled enzymes) | ClinicalTrials.gov |
| Primary | Intrarenal artery | Change from baseline renal arterial resistive index (RI) at 12 weeks. | Intrarenal artery will be measured by renal blood flow in renal arterial resistive index (RI) with ultrasonography equipment EPIQ 5G, Phillips. | ClinicalTrials.gov |
| Primary | Post Occlusive Reactive Hyperemia; PORH | Change from baseline Post Occlusive Reactive Hyperemia; PORH at 12 weeks. | Evaluation of blood flow to the skin area in percent will be measured by Post Occlusive Reactive Hyperemia in percent; PORH with Laser Doppler flowmeter, Perimed AB, Sweden. | ClinicalTrials.gov |
| Primary | Cerebral blood flow | Change from baseline cerebral blood flow at 12 weeks | Cerebral blood flow in centimeter per second will be measure with ultrasonography equipment (EPIQ 5G, Phillips). | ClinicalTrials.gov |
| Primary | Cerebrovascular conductance index | Change from baseline cerebrovascular conductance index at 12 weeks | Cerebrovascular conductance index in cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips). | ClinicalTrials.gov |
| Primary | Cerebrovascular reactivity index | Change from baseline cerebrovascular reactivity index at 12 weeks | Cerebrovascular reactivity index in %cm/sec/mmHg will be measured with ultrasonography equipment (EPIQ 5G, Phillips). | ClinicalTrials.gov |
| Primary | Arterial compliance | Change from baseline Arterial compliance at 12 weeks | Arterial compliance in units will be measure by carotid diameter during systolic and diastolic with ultrasonography equipment (EPIQ 5G, Phillips) and systemic blood pressure with (VP-1000 plus, omrom Healthcare). | ClinicalTrials.gov |
| Primary | Pulsatility index | Change from baseline Pulsatility index at 12 weeks.] 12.Montreal Cognitive Assessment | Pulsatility index in units will be measure with ultrasonography equipment (EPIQ 5G, Phillips). | ClinicalTrials.gov |
| Primary | Montreal Cognitive Assessment | Change from baseline Montreal Cognitive Assessment at 12 weeks.] | Montreal Cognitive Assessment in score (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function. | ClinicalTrials.gov |
| Primary | Mini-Mental State Examination | Change from baseline Mini-Mental State Examination at 12 weeks.] | Mini-Mental State Examination in scores (0 - 30 scores) cut off below 25 scores that indicate impairment cognitive function. | ClinicalTrials.gov |
| Primary | Trail Making Test-B | Change from baseline Trail Making Test-B at 12 weeks | Trail Making Test-B in second cut off below 101 seconds that indicate dementia. | ClinicalTrials.gov |
| Primary | Fasting blood sugar | Change from baseline fasting blood sugar at 12 weeks.] | Fasting blood sugar in mg/dl will be measure with enzymatic assay using hexokinase reaction. | ClinicalTrials.gov |
| Primary | Glycosylated hemoglobin | Change from baseline Glycosylated hemoglobin at 12 weeks.] | Glycosylated hemoglobin in percent will be measure with enzymatic assay using hexokinase reaction. | ClinicalTrials.gov |
| Primary | Homeostasis Model Assessment of insulin resistance | Change from baseline Homeostasis Model Assessment of insulin resistance at 12 weeks.] | Homeostasis Model Assessment of insulin resistance in units will be calculated with Fasting blood sugar and insulin. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)